The role of sentinel lymph node biopsy in the diagnosis and prognosis of malignant melanoma;La biopsia del ganglio centinela: Su papel diagnóstico y pronóstico en el melanoma maligno

Actas Dermo-Sifiliograficas

Volumn 99, Issue 5, 2008, Pages 331-348

  Mangas, Cristina ^a,b   Paradelo, C ^a   Rex, J ^a   Ferrandiz C ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Servicio de Oncologia   (Spain)

Author keywords

Melanoma; Prognosis; Sentinel lymph node

Indexed keywords

ALPHA2B INTERFERON; EOSIN; GANGLIOSIDE GD2; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; HEMATOXYLIN; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; N ACETYLGALACTOSAMINYLTRANSFERASE; TECHNETIUM 99M; TRANSCRIPTION FACTOR PAX3; TUMOR ANTIGEN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOGENESIS; MELANOMA; PROGNOSIS; RADIOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCINTISCANNING; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION;

FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; MELANOMA; PATIENT SELECTION; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 45749121854     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(08)70267-1     Document Type: Review

References (97)

1. Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J, et al. Molecular diagnostics in melanoma. J Am Acad Dermatol. 2005;52:743-75.
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-8.
3. Balch CM, Soong S, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-49.
4. Thompson JF, Shaw HM, Hersey P, Scoyler R. The history and future of melanoma staging. J Surg Oncol. 2004;86:224-35.
5. Thompson JF, Stretch JR, Uren RF, Ka VS, Scoyler R. Sentinel node biopsy for melanoma: where have we been and where are we going. Ann Surg Oncol. 2004;11:147S-51S.
6. Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum Pathol. 2000;31:327-31.
7. Baron JM, Abuzahra F. Evidence-based staging system for malignant melanoma: is new necessarily better? Letter. Cancer. 2004;364:395-6.
8. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-73.
9. Nagore E, Oliver V, Botella R, Insa A, Fortea JM. Factores pronósticos en el melanoma maligno cutáneo localizado: estudio de 639 pacientes. Med Clin (Barc). 2005;124:361-7.
10. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles. Am J Pathol. 2004;164:193-203.
11. Balch CM, Houghton AN, Sober AJ, Soong S. Cutaneous Melanoma. 4th ed. St. Louis, Missouri: Quality Medical Publishing, Inc.; 2003.
12. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma:evidence assessment. J Am Acad Dermatol. 2006;54:19-27.
13. Bittner M, Meltxer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-40.
14. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456-66.
15. Gould EA, Winship T, Philbin PH, Kerr HH. Observations on a «sentinel node» in cancer of the parotid. Cancer. 1960;13:77-8.
16. Morton DL, Wen Dr, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperativey lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-9.
17. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The ordely progression of melanoma nodal metastases. Ann Surg. 1994;220:759-67.
18. Thompson JF, McCarthy WH, Bosch CM, O'Brien CJ, Quinn MJ, Paramaesvaran S, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph node. Melanoma Res. 1995;5:255-60.
19. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. A multicenter trial. Ann Surg. 1999;230:453-65.
20. Bleiweiss IJ. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles. Lancet Oncol. 2006;7:686-92.
21. Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneous malignancy. Laryngoscope. 2006;112:1-15.
22. Leong SP. Selective sentinel lymphadenectomy for malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma. Cancer Treat Res. 2005;127:39-76.
23. Thomas KA, Lechner J, Shen P, Waters GS, Geisinger KR, Levine EA. Use of sentinel node mapping for cancer of the colon: «to map or not to map». Am Surg. 2006;72:606-11.
24. Medalie N, Ackerman AB. Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now. Br J Dermatol. 2004;151:298-307.
25. Thomas JM, Patocskai EJ. The argument against sentinel node biopsy for malignant melanoma. Its use should be confined to patients in clinical trials. Br Med J. 2000;321:3-4.
26. Gutzmer R, Al-Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival-a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137-41.
27. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Inmediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet. 1998;351:793-6.
28. Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Cáceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-30.
29. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;62:697-705.
30. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-63.
31. Paradelo C, Fraile M, Ferrándiz C, Alastrué A, Bigatà X. La linfogammagrafía en el estudio de los patrones de drenaje linfático en los pacientes con melanoma. Med Clin (Barc). 1999;113:281-4.
32. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
33. Ferrándiz C. Biopsia del ganglio centinela en el melanoma. Consideraciones para la selección de los pacientes. Med Clin (Barc). 2003;120:737-8.
34. Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12:429-39.
35. Guitart J, Lowe L, Piepkorn L, Prieto VG, Rabkin MS, Ronan SG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138:603-8.
36. Urso C, Borgnoni L, Saieva C, Ferrara G, Tinacci G, Begliomini B, et al. Sentinel lymph node biopsy in patients with «atypical Spitz tumors». A report on 12 cases. Hum Pathol. 2006;37:816-23.
37. Thompson JF, Niewind P, Uren RF, Bosch CM, Howman-Giles R, Vrouenraets BC, et al. Single-dose isotope injection for both preoperative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res. 1997;7:500-6.
38. McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212-23.
39. Abrahansen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma:extended histopathologic evaluation improves diagnostic precision. Cancer. 2004;100:1683-91.
40. Van Akkooi AC, Wilt JH, Verhoef C, Graveland WJ, van Geel AN, Kliffen M, et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006;42:372-80.
41. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17:3238-44.
42. Cook MG, Green MA, Anderson A, Eggermont AM, Ruiter DJ, Spatz A, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003;200:314-9.
43. Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231:795-803.
44. Starz H, Balda BR, Kramer KU, Buchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110-20.
45. Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res. 2003;13:511-20.
46. Spanknebel K, Coit DG, Bieglick SC, Gonen M, Rosai J, Klimstra DS. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology. Am J Surg Pathol. 2005;29:305-17.
47. Roberts AA, Cochran AJ. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol. 2004;85:152-61.
48. Cochran AJ, Wen DR, Morton DL. Occult tumour cells in the lymph nodes of patients with pathological stage I malignant melanoma: an inmunohistoligical study. Am J Surg Pathol. 1988;12:612-8.
49. Mangas C, Fernández-Figueras MT, Carrascosa JM, Soria X, Paradelo C, Ferrandiz C, et al. A tattoo reaction in a sentinel lymph node from a patient with melanoma. Dermatol Surg. 2007;33:766-7.
50. Fontaine D, Parkhill W, Greer W, Walsh N. Nevus cells in lymph nodes. Am J Dermatopathol. 2002;24:1-5.
51. Carson K, Wen DR, Li PX, Lana AM, Bailly C, Morton DL, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol. 1996;20:834-40.
52. Holt JB, Saguenza OP, Levine EA, Shen P, Bergman S, Geisinger KR, et al. Nodal melanocytic nevi in sentinel lymph nodes. Am J Clin Pathol. 2004;121:58-63.
53. Cserni G. A model of determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57:467-71.
54. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol. 2003;10:575-81.
55. Cochran AJ, Roberts AA. Optimized assessment of sentinel lymph nodes for metastatic melanoma: implications for regional surgery and overall treatment planning. Ann Surg Oncol. 2004;11:156S-61S.
56. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, Gietema HA, Molenkamp BG, Statius Muller MG, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol. 2005;12:440-8.
57. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991;338:1227-9.
58. Wang X, Heller R, vanVoorhis N, Glass F, Fenske N, Berman C, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220:768-74.
59. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, MacZey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114:637-42.
60. Goydos JS, Patel KN, Shih WJ, Lu SE, Yudd AP, Kempf JS, et al. Patterns of recurrence in patients with melanoma and histological negative but RT-PCR-positive sentinel lymph nodes. J Am Coll Surg. 2003;196:196-204.
61. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004;22:3989-96.
62. Kuo CT, Hoon DS, Takeuchi H, Turner R, Wang HJ, Morton DL, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21:3566-72.
63. Mangas C, Hilari JM, Paradelo C, Rex J, Fernández-Figueras MT, Fraile M, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by RTPCR for tyrosinase in melanoma patients. Ann Surg Oncol. 2006;13:910-8.
64. Ribuffo D, Gardilone A, Vonella M, Chiummariello S, Cigna E, Haliassos N, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol. 2003;10:396-402.
65. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24:2849-57.
66. Giese T, Engstner M, Mansmann U, Hartschuh W, Arden B. Quantification of melanoma micromestastases in sentinel nodes using real-time RT-PCR. J Invest Dermatol. 2005;124:633-7.
67. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280:1410-5.
68. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22:2671-80.
69. Ulrich J, Bonnekoh B, Bockelmann R, Schön M, Schön MP, Steinke R, et al. Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer. 2004;40:2812-9.
70. Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol. 2007;25:1588-95.
71. Kawakami Y, Eliyahu S, Delgado C. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3315-9.
72. Reintgen DS, Jakub JW, Pendas S, Swor G, Giuliano R, Shivers S. The staging of malignant melanoma and the Florida Melanoma Trial. Ann Surg Oncol. 2004;11:186S-91S.
73. Godfrey T, Kelly A. Development of quantitative reverse transcriptase PCR assays for measuring gene expression. Methods Mol Biology. 2005;291:423-45.
74. Davids V, Kidson SH, Hanekom GS. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node. Melanoma Res. 2003;13:313-24.
75. Haigh PI, Lucci A, Turner RR, Bostick PJ, Krasne DL, Stern SL, et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer. 2001;92:535-41.
76. Scolyer RA, Thompson JF, Li LX, Beavis A, Dawson M, Doble P, et al. Failure to remove true sentinel nodes can cause failure of teh sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol. 2004;11:174S-8S.
77. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253-60.
78. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg. 2001;233:250-8.
79. Morton DL, Cochran AJ. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol. 2004;151:308-19.
80. Fidler IJ. The pathogenesis of cancer metastasis: the «seed and soil» hypothesis revisited. Nat Rev Cancer. 2003;3:1-6.
81. Pizarro A, Redondo P. Melanoma dissemination and the usefulness of sentinel lymph node: a reappraisal. Skin Cancer. 2004;19:221-30.
82. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-3.
83. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587-96.
84. Van Poll DV, Thompson JF, Colman MH, McKinnon JG, Saw RP, Stretch JR, et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol. 2005;12:597-608.
85. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6:442-9.
86. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134:381-7.
87. Statius Muller MG, van Leeuwen PA, de Lange-de Klerk ES, van Diest PJ, Pijpers R, Ferwerda CC, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer. 2001;91:2401-8.
88. Jansen L, Niegew OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87: 484-9.
89. Harlow SP, Krag DN, Ashikaga T, Hoefnagel CA, Olmos RA, Kroon BB. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res. 2001;11:45-55.
90. Doting MH, Hoekstra HJ, Plukker JT, Piers DA, Jager PL, Tiebosch AT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol. 2002;28:673-8.
91. Chao C, Wong SL, Ross MI, Reintgen DS, Noyes RD, Cerrito PB, et al. Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg. 2002;184:520-4.
92. Vidal-Sicart S, Pons F, Puig S, Ortega M, Vilalta A, Martín F, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging. 2003;30:362-6.
93. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, et al. Lymphatic mapping and sentinel lymphadenectomy for early stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal metastases. Ann Surg. 2003;238:538-49.
94. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13:1655-63.
95. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005;14:1016-22.
96. Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Fraile M, et al. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases. Dermatol Surg. 2005;31:1385-93.
97. Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003;112:486-97.